top of page
Photo of site author, Shelly Albaum

Shelly Albaum

Editor, Science of NAD

Important Disclosures

1. This is my personal website

All opinions are my own. Nobody writes here but me.

2. Supplements Are Not Medicines

Health Supplements like nicotinamide riboside are not intended to cure or treat any disease, condition, or illness.

3. No Medical Advice

I am a lawyer and a journalist, not a doctor, and I offer no medical advice. But I do follow the science, and I can bring to your attention

some interesting studies. You can read more about me here. And check with your physician -- your physician can look at this research, too.

4. Commercial Affiliations

I am a ChromaDex shareholder, and a marketing affiliate for Amazon and Rakuten. As a result, I will sometimes mention or recommend products that I endorse, like Tru Niagen, which I take every day. I may earn a small commission from qualifying purchases if you were referred directly from this site and completed a purchase. [Thank you!] You can read more about our advertising, privacy, and data collection policies here

Which is Better - NR or NMN?

NR and NMN can both boost NAD levels in most tissues. But how they do that, and the cost to get the effect, makes NR the choice easy: less turns out to be more...

Which is better - NMN or NR?

NMN mostly works as a reliable way of delivering NR and/or NAM to your cells.

The problems with NMN as an NAD precursor, then, are that (1) it costs more than NR or NAM, and (2) part of what you are paying for is a bunch of phosphate molecules that are going to be discarded. That means that a gram of NMN delivers less NR to your cells than a gram of NR does. Another way of thinking about that is that NMN contains filler. And the filler is quite a bit by weight, because the molecular weight of NMN -- 334 grams per mole -- is about 30% higher than NR, which is 255 grams per mole.

So does that mean you would be better off just supplementing with NR or NAM than using NMN? Probably, but there are still a couple wrinkles left to consider...

bottom of page